Cargando…

Protocol to differentiate glycosylphosphatidylinositol-anchored prion protein from pro-prion protein in cancer cells

Defects of glycosylphosphatidylinositol (GPI)-anchor synthesis lead to the production of pro-proteins with altered functions. However, pro-protein-specific antibodies for functional analysis are lacking. Here, we present a protocol to differentiate GPI-anchored prion protein (PrP) from pro-PrP in ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huan, Yang, Jie, Li, Jingfeng, Gao, Zhenxing, Xu, Jiang, Li, Chaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323115/
https://www.ncbi.nlm.nih.gov/pubmed/37329508
http://dx.doi.org/10.1016/j.xpro.2023.102298
Descripción
Sumario:Defects of glycosylphosphatidylinositol (GPI)-anchor synthesis lead to the production of pro-proteins with altered functions. However, pro-protein-specific antibodies for functional analysis are lacking. Here, we present a protocol to differentiate GPI-anchored prion protein (PrP) from pro-PrP in cancer cells using a complementary approach applicable to other GPI-anchored proteins. We first describe steps for phosphatidylinositol-specific phospholipase C treatment and flow-cytometry-based detection. We then detail the carboxypeptidase Y (CPDY) assay including antibody immobilization, affinity purification, CPDY treatment, and western-blot-based detection. For complete details on the use and execution of this protocol, please refer to Li et al. (2022).(1)